ABBV vs ADBE: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Adobe Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Adobe Inc. · Technology
$219.72
+45.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
ADBE has more upside to fair value
(+45.0%).
ADBE trades at a lower forward P/E
(12.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
ADBE |
| Current Price |
$261.07 |
$219.72 |
| Fair Value Estimate |
$264.30 |
$318.59 |
| Upside to Fair Value |
+1.2%
|
+45.0%
|
| Market Cap |
$461.3B |
$87.3B |
| Forward P/E |
128.0x
|
12.6x
|
| EV / EBITDA |
31.0x
|
9.0x
|
| Price / Sales |
7.3x
|
3.5x
|
| Price / FCF |
22.1x
|
8.2x
|
| Revenue Growth YoY |
+12.4%
|
+12.7%
|
| Gross Margin |
70.7%
|
89.1%
|
| Operating Margin |
27.6%
|
36.1%
|
| Return on Equity |
68.0%
|
62.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
12.17%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Adobe Inc. is a leading software company specializing in digital media and digital experience solutions, driven primarily by subscription-based revenue models. The company benefits from a high-quality business model characterized by a durable competitive moat, strong margins with a gross margin of 89.1% and operating margin of 36.1%, and robust return on equity at 62.4%. Despite solid revenue gro…
Accumulation Zones
| Metric |
ABBV |
ADBE |
| Zone Low |
$198.23 |
$238.94 |
| Zone High |
$224.66 |
$270.80 |
| In Buy Zone? |
No
|
Yes
|